SEC Form 4	
------------	--

### FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per respon	se: 0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	т	able I - Non-Deriva	ative Securities Acquired, Disposed of, or Benefi	cially	Owned					
(City)	(State)	(Zip)	X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							
	UA	94020	Rule 10b5-1(c) Transaction Indication							
(Street) MENLO PARK	<u> </u>	94025			Form filed by More thar Person	n One Reporting				
149 COMMON	149 COMMONWEALTH DRIVE			X						
	CORPORATED		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	idual or Joint/Group Filing	g (Check Applicable				
C/O CORCEPT	. ,	· · ·	10/02/2023		Chief Accounting Officer					
(Last)	(First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year) 10/02/2023	X	Officer (give title below)	Other (specify below)				
1. Name and Address of Reporting Person <sup>*</sup> Lyon Joseph Douglas			2. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC</u> [ CORT ]		tionship of Reporting Pers all applicable) Director	son(s) to Issuer 10% Owner				
			or Section So(n) of the investment Company Act of 1940							

Table 1- Non-Derivative Securities Acquired, Disposed of, of Derivitiany Owned												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.					5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
Common Stock	10/02/2023		М		2,418	A	\$11.35	8,272(1)	D			
Common Stock	10/02/2023		<b>S</b> <sup>(2)</sup>		2,418	D	\$27.2493 <sup>(3)</sup>	5,854 <sup>(1)</sup>	D			

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock option (right to buy)	\$11.35	10/02/2023		М			2,418	(4)	02/08/2029	Common Stock	2,418	\$0	2,418	D	

#### Explanation of Responses:

1. Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from \$27.24 to \$27.28. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

4. Fully exercisable.

#### /s/ Joseph Douglas Lyon

\*\* Signature of Reporting Person

<u>10/04/2023</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.